Savara (SVRA) Projected to Post Quarterly Earnings on Thursday

Savara (NASDAQ:SVRA) is expected to announce its earnings results before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter.

Savara Price Performance

Savara stock opened at $2.39 on Wednesday. Savara has a 52 week low of $2.26 and a 52 week high of $5.70. The business has a 50-day simple moving average of $2.83 and a 200 day simple moving average of $3.45. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13. The stock has a market cap of $410.17 million, a price-to-earnings ratio of -5.56 and a beta of 0.63.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on SVRA shares. Wells Fargo & Company began coverage on Savara in a research report on Friday, December 20th. They set an “overweight” rating and a $8.00 target price for the company. Evercore ISI reiterated an “in-line” rating and issued a $5.00 price objective (down from $7.00) on shares of Savara in a report on Wednesday, November 13th. JMP Securities reiterated a “market outperform” rating and issued a $9.00 price objective on shares of Savara in a report on Thursday, December 19th. Finally, HC Wainwright cut their price objective on Savara from $10.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Savara presently has an average rating of “Moderate Buy” and an average price target of $8.83.

Insider Activity at Savara

In related news, CEO Matthew Pauls sold 54,702 shares of the stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $3.31, for a total transaction of $181,063.62. Following the completion of the sale, the chief executive officer now directly owns 1,536,379 shares in the company, valued at $5,085,414.49. This represents a 3.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 5.13% of the stock is currently owned by company insiders.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.